Long-Term Outcomes of Stereotactic Radiosurgery for Vestibular Schwannoma Associated with Neurofibromatosis Type 2 in Comparison to Sporadic Schwannoma
Authors:
- Yuki ShinyaYSYuki Shinya
- Hirotaka HasegawaHirotaka Hasegawa
- Masahiro ShinMSMasahiro Shin
- Takehiro SugiyamaTSTakehiro Sugiyama
- Mariko KawashimaMKMariko Kawashima
- Wataru TakahashiWTWataru Takahashi
- Shinichi IwasakiSIShinichi Iwasaki
- Akinori KashioAKAkinori Kashio
- Hirofumi NakatomiHNHirofumi Nakatomi
- Nobuhito SaitoNSNobuhito Saito
Open Access
Abstract
The efficacy of radiosurgery for neurofibromatosis type 2 (NF2)-associated vestibular schwannoma (VS) remains debatable. We retrospectively analyzed radiosurgical outcomes for NF2-associated VS compared to sporadic VS using our database of 422 consecutive VS patients. Twenty-five patients with 30 NF2-associated VSs with a mean follow-up of 121 months were identified. NF2-associated VSs exhibited excellent tumor control (10-year cumulative rate, 92% vs. 92% in sporadic VSs; p = 0.945) and worse overall survival (73% vs. 97%; p = 0.005), mainly due to tumor progression other than the treated VSs. The presence of NF2 was not associated with failed tumor control via multivariate Cox proportional hazard analyses. No difference in radiation-induced adverse events (RAEs) was confirmed between cohorts, and prescription dose (hazard ratio 8.30, 95% confidence interval 3.19–21.62, p < 0.001) was confirmed as a risk for cranial nerve injuries via multivariate analysis. Further analysis after propensity score matching using age, volume, and sex as covariates showed that NF2-associated VSs exhibited excellent local control (100% vs. 93%; p = 0.240) and worse overall survival (67% vs. 100%; p = 0.002) with no significant difference in RAEs. Excellent long-term tumor control and minimal invasiveness may make radiosurgery a favorable therapeutic option for NF2 patients with small to medium VS, preferably with non-functional hearing or deafness in combination with postoperative tumor growth or progressive non-operated tumors, or with functional hearing by patients’ wish.Keywords
This publication has 56 references indexed in Scilit:
- Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuationAnnals of Oncology, 2010
- Malignant Transformation of Acoustic Neuroma/Vestibular Schwannoma 10 Years after Gamma Knife Stereotactic RadiosurgeryJournal of Neurological Surgery Part B: Skull Base, 2010
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2Neuro-Oncology, 2009
- Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2Cancer, 2009
- Radiosurgery for Type II Neurofibromatosis2008
- Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspectiveThe Lancet Neurology, 2007
- Hearing preservation surgery for neurofibromatosis Type 2–related vestibular schwannoma in pediatric patientsJournal of neurosurgery. Pediatrics, 2007
- STEREOTACTIC RADIOSURGERY FOR VESTIBULAR SCHWANNOMAS IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2Neurosurgery, 2007
- Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosisJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Early Proactive Management of Vestibular Schwannomas in Neurofibromatosis Type 2Neurosurgery, 2001